Treatment of germ cell tumors - Update 2006

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Kollmannsberger, C ^a   Honecker, F ^b   Bokemeyer, C ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEMCITABINE; GLUTATHIONE; IRINOTECAN; METALLOTHIONEIN; OXALIPLATIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; VASCULOTROPIN INHIBITOR; VINBLASTINE;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHROMOSOME 15Q; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 2P; CHROMOSOME 7Q; CHROMOSOME 9Q; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COOPERATION; CORONARY ARTERY DISEASE; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; FOLLOW UP; GENE AMPLIFICATION; GERM CELL TUMOR; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LYMPH NODE METASTASIS; MALE; MALE GENITAL SYSTEM SURGERY; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; METASTASIS POTENTIAL; MICROALBUMINURIA; MOLECULAR MECHANICS; OBESITY; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; RISK BENEFIT ANALYSIS; TESTIS CANCER; TREATMENT OUTCOME;

HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 33749604579     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl232     Document Type: Article

References (58)

1. Mead G, Group ftlGCCC. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
2. Culine S, Kerbrat P, Bouzy J et al. The optimal chemotherapy regimen for good-risk metastatic non-seminomatous germ cell tumors (MNSGCT) is 3 cycles of bleomycin, etoposide and cisplartin. Mature results of a randomized trial. Proc Am Soc Clin Oncol 2603; 22: 382 (abstr 1536).
3. Kondagunta VG, Back J, Bajorin D et al. Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. J Clin Oncol 2005; 23: 9290-9294.
4. Niedner H, Christen R, Lin et al. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 2001; 60: 1153-1160.
5. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
6. Masters JR, Koberle B. Curing metastatic cancer: Lessons from testicular germ-cell tumours. Nature Rev Cancer 2003; 3: 517-525.
7. Sark MW, Timmer-Bosscha H, Meijer C et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Brit J Cancer 1995; 71: 684-690.
8. Mayer F, Stoop H, Scheffer GL et al. Molecular Determinants of Treatment Response in Human Germ Cell Tumors Clin Cancer Res 2003; 9: 767-773.
9. Scheffer GL, Schroiejers AB, Izquierdo MA et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000; 12: 550-556,
10. Koberle B, Grimaldi KA, Sunters A et al. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997; 70: 551-555.
11. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-276.
12. Koberle B, Payne J, Grimaldi KA et al. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 1996; 52: 1729-1734.
13. Welsh C, Day R, McGurk C et al. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004; 110: 352-361.
14. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med 1996; 2: 804-810.
15. Lutzker SG. P53 tumour suppressor gene and germ cell neoplasia. APMIS 1998; 106: 85-89.
16. Lutzker SG, Mathew R, Taller DR. A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 2001; 20: 2982-2986.
17. Burger H, Nooter K, Boersma AW et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999; 81: 620-628.
18. Kersemaekers AM, Mayer F, Moller M et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 2002; 20: 1551-1561.
19. Mayer F, Gillis AJ, Dinjens W et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 2002; 62: 2758-2760.
20. Mayer F, Honecker F, Looijenga LH, Bokemeyer C. Towards an understanding of the biological casis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 2003; 14: 825-832.
21. Rao PH, Houldsworth J, Palanisamy N et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 1998; 58: 4260-4263.
22. Classen J, Schmidberger H, Meisner C et al. Para-aortic irradiation for stage I testicular seminoma: Results of a prospective study in 675 patents. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 2004; 90: 2305-2311.
23. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality After Cure of Testicular Seminoma J Clin Oncol 2004; 22: 640-647.
24. Jones WG, Fossa SD, Mead G et al. Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testicular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005; 23: 1200-1208.
25. Oliver RT, Mason M, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: A randomised trial. Lancet 2005; 366: 293-300.
26. Oliver T, Dieckmann K, Steiner H, Skoneczna I. Pooled analysis of Phase 2 reports of 2 v 1 course of Carboplatin as adjuvant for Stage 1 Seminoma. Proc Am Soc Clin Oncol 2005; 24: Abstr 4572.
27. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003; 111: 75-65.
28. Warde P, Specht L, Horwich A et al. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis. 2002; 20: 4448-4452.
29. Kollmannsberger C, Kuzcyk M, Mayer F et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999; 17: 275-281,
30. Travis LB, Fosså SD, Schonfeld SJ et al. Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors. J Natl Cancer Inst 2005; 97: 1354-1365.
31. Nuver J, Smit AJ, van der Meer J et al. Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer. J Clin Oncol 2005; 23: 9130-9137.
32. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncoll 2000; 18: 1725-1732.
33. Sagstuen H, Aass N, Fosså SD et al. Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer J Clin Oncol 2005; 23: 4980-4990.
34. Van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-475.
35. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
36. Porcu P, Bhatia S, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 2000; 18: 1181-1186.
37. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22: 108-114.
38. Pectasides D, Pectasides M, Farmakis D et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: A phase II study. Ann Oncol 2004; 15: 493-497.
39. Pizzocaro G, Nicolai N, Salvioni R, Gianni L. Paciltaxel, cisplatin and gemcitabine (TPG) third line therapy in metastatic germ cell tumors (GCT) of the testis. Proc Am Soc Clin Oncol 2001; 20: Abstr 773.
40. De Giorgi U, Rosti G, Papiani G et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: Preliminary experience. Am J Clin Oncol 2004; 27: 457-460.
41. Steiner H, Hoeltl L, Wirtenberger W et al. Long-term experience with carboplatin monotherapy for clinical stage I seminoma: A retrospective single-center study. Urology 2002; 60: 324-328.
42. Oliver RTD, Boublikova L, Ong J. Fifteen Year Follow up of the Anglian Germ Cell Cancer Group Adjuvant Studies of Carboplatin as an Alternative to Radiation or Surveillance for Stage 1 Seminoma. Proc Am Soc Clin Oncol 2001; 21: Abstr 780.
43. Reiter WJ, Brodowicz T, Alavi S et al. Twelve-Year Experience With Two Courses of Adjuvant Single-Agent Carboplatin Therapy for Clinical Stage I Seminoma. J Clin Oncol 2001; 19: 101-104.
44. Dieckmann KP, Bruggeboes B, Pichlmeier U et al. Adjuvant treatment of clinical stage I seminoma: Is a single course of carboplatin sufficient? Urology 2000; 55: 102-106.
45. Nost G, Lipsky H, Wurnschimmel E. Carboplatin monotherapy in clinical stage I of seminoma. An acceptable alternative? Urology A 1998; 37: 629-634.
46. Krege S, Kalund G, Otto T et al. Phase II study: Adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 1997; 31: 405-407.
47. Horwich A, Alsanjari N, A'Hern R et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992; 65: 775-778.
48. Choo R, Thomas G, Woo T et al. Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005; 61: 736-740.
49. Warde PR, Chung P, Sturgeon J et al. Should Surveillance should be considered the standard of care in stage I seminoma? Proc Am Soc Clin Oncol 2005; 24: Abstr 4520.
50. Motzer RJ, Bajorin D, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ call tumors. J Clin Oncol 1994; 12: 2277-2283.
51. Bokemeyer C, Hartmann JT, Kuczyk MA et al. The role of paclitaxel in chemosensitive urological malignancies: Current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 1996; 14: 354-359.
52. Bokemeyer C, Gerl A, Schoffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999; 17: 512-516.
53. Einhorn LH, Stender W, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999; 17: 509-511.
54. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20: 2031-2037.
55. Hinton S, Catalano PJ, Einhorn L et al. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol 2001; 20: 1859-1863.
56. Miki T, Mizutani Y, Nonomura N et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 2002; 95: 1879-1885.
57. Theodore C, Flechon A, Fizazi K et al. A phase II multicentre study of oxaliplatin (Ox) in combination with paclitaxel (Px) in patients (pts) who failed cisplatin (CDDP) based chemotherapy (CT) for germ cell tumors (GCT). Proc Am Soc Clin Oncol 2004; 23: 389 (abstract 4534).
58. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: A phase II study. Eur Urol 2004; 46: 216-221.